Jeffrey E Rubnitz
Overview
Explore the profile of Jeffrey E Rubnitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
6679
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kamens J, Nance S, Koss C, Xu B, Cotton A, Lam J, et al.
Nat Commun
. 2023 Feb;
14(1):809.
PMID: 36781850
Rearrangments in Histone-lysine-N-methyltransferase 2A (KMT2Ar) are associated with pediatric, adult and therapy-induced acute leukemias. Infants with KMT2Ar acute lymphoblastic leukemia (ALL) have a poor prognosis with an event-free-survival of 38%....
22.
Marrero R, Cao X, Wu H, H Elsayed A, Klco J, Ribeiro R, et al.
Blood Adv
. 2023 Jan;
7(11):2538-2550.
PMID: 36689724
Cytarabine arabinoside (Ara-C) has been the cornerstone of acute myeloid leukemia (AML) chemotherapy for decades. After cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts...
23.
Pfeiffer T, Li Y, Ashcraft E, Karol S, Rubnitz J, Epperly R, et al.
Bone Marrow Transplant
. 2022 Nov;
58(3):328-331.
PMID: 36443431
No abstract available.
24.
Mangum D, Bishop J, Zhou Y, Cheng C, Karol S, Rubnitz J, et al.
Br J Haematol
. 2022 Nov;
200(3):338-343.
PMID: 36352514
Of 1003 children with acute lymphoblastic leukaemia (ALL), 147 (14.7%) presented without peripheral blood blasts (PBB). While absence of PBB was not independently associated with survival outcomes when compared to...
25.
Gruber T, Pei D, Choi J, Cheng C, Coustan-Smith E, Campana D, et al.
Blood Adv
. 2022 Oct;
6(24):6131-6134.
PMID: 36251744
No abstract available.
26.
Ryland G, Umeda M, Holmfeldt L, Lehmann S, Herlin M, Ma J, et al.
Blood
. 2022 Sep;
141(7):800-805.
PMID: 36179268
No abstract available.
27.
Zarnegar-Lumley S, Caldwell K, Rubnitz J
Leukemia
. 2022 Jun;
36(8):1951-1960.
PMID: 35668109
Pediatric acute myeloid leukemia (AML) develops from clonal expansion of hematopoietic precursor cells and is characterized by morphologic and cytomolecular heterogeneity. Although the past 40 years have seen significant improvements...
28.
Inaba H, van Oosterwijk J, Panetta J, Li L, Buelow D, Blachly J, et al.
Clin Cancer Res
. 2022 Mar;
28(12):2536-2546.
PMID: 35344039
Purpose: To evaluate the safety, activity, and emergence of FLT3-kinase domain (KD) mutations with combination therapy of crenolanib and sorafenib in acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD)....
29.
Iijima M, Stall M, Wang L, Panetta J, Triplett B, Pui C, et al.
Blood Adv
. 2022 Feb;
6(9):2824-2834.
PMID: 35196375
Little is known about body composition changes in patients with acute myeloid leukemia (AML) during and after treatment or their associations with outcomes. Z-scores for body mass index (BMI), weight,...
30.
Umeda M, Ma J, Huang B, Hagiwara K, Westover T, Abdelhamed S, et al.
Blood Cancer Discov
. 2022 Feb;
3(3):194-207.
PMID: 35176137
Significance: We defined the spectrum of mutations in relapsed pediatric AML and identified UBTF-TDs as a new recurrent genetic alteration. These duplications are more common in children and define a...